Thomas Jan, DO
Pain Medicine · Massapequa, NYNPI 1871685404
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $18,000 of the $21,740 with a category attached, or 82.8%. MDD US Operations, LLC accounts for 66.8% of it on its own, with 18 other manufacturers making up the rest. Reporting peaked in 2019 at $20,120 and has fallen 99.6% since, to $90 in 2025. Among pain medicine clinicians in NY with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 170 payments — averaging $127.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- MDD US Operations, LLC$15K
- Indivior Inc.$5K
- Collegium Pharmaceutical, Inc.$441
- Alkermes, Inc.$379
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$266
- AbbVie$233
- plus $602 from 13 others
What the payments were for
- Speaking & faculty fees$18,00083%
- Travel & lodging$7463%
- Food & beverage$2,88213%
- Education$1121%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| MDD US Operations, LLC | 46 | $14,527 |
| Indivior Inc. | 21 | $5,292 |
| Collegium Pharmaceutical, Inc. | 32 | $441 |
| Alkermes, Inc. | 21 | $379 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 16 | $266 |
| AbbVie(2 entities) | 10 | $233 |
| Averitas Pharma Inc. | 2 | $120 |
| Johnson & Johnson | 5 | $86 |
| Scilex Pharmaceuticals Inc. | 3 | $60 |
| Medtronic | 2 | $58 |
| Assertio Therapeutics, Inc. | 3 | $53 |
| Pacira Pharmaceuticals Incorporated | 1 | $45 |
| Pacira Therapeutics, Inc. | 1 | $36 |
| Redhill Biopharma Inc. | 2 | $34 |
| Forte Bio-pharma LLC | 1 | $32 |
| Ferring Pharmaceuticals Inc. | 1 | $23 |
| Atricure, Inc. | 1 | $22 |
| Teva Pharmaceuticals USA, Inc. | 1 | $17 |
| Almatica Pharma LLC | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Lucemyra/Lofexidine$14,105
- SUBLOCADE$4,993
How this compares
$21,740 in reported general payments places this provider in the 90th percentile of 503 pain medicine providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OxycontinOxycodone Hcl | 165 | $170,188 |
| Xtampza ErOxycodone Myristate | 42 | $44,064 |
| SublocadeBuprenorphine | 13 | $24,968 |
| Morphine Sulfate ErMorphine Sulfate | 207 | $15,310 |
| TopamaxTopiramate | 11 | $14,353 |
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 53 | $10,464 |
| Tizanidine Hcl | 376 | $2,783 |
| Fentanyl | 34 | $2,680 |
| Buprenorphine | 11 | $2,603 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 131 | $2,210 |
| Duloxetine Hcl | 95 | $2,122 |
| Gabapentin | 169 | $2,015 |
| Pregabalin | 69 | $1,774 |
| Oxycodone Hcl | 163 | $1,584 |
| Methylprednisolone | 160 | $1,028 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Collegium Pharmaceutical, Inc.Xtampza Er | $441 | $44,06442 claims |
| Indivior Inc.Sublocade | $5,292 | $24,96813 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 503 pain medicine providers in New York.
Other pain medicine in Massapequa
- Gary SchwartzBrooklyn$756K
- Amitabh GulatiNew York$614K
- William CaldwellStony Brook$530K
- Brian DurkinPort Jefferson$455K
- David SpinnerNew York$391K
- Grace FordeNew Hyde Park$355K
- Romanth WaghmaraeHamburg$158K
- Samuel BrownSouthold$147K
- Fred CohenBronx$141K
- Eric LeeNew York$117K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.